CoChat

Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Rajasekhar, Megha, Simpson, Julie A, Ley, Benedikt, Edler, Peta, Chu, Cindy S, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Bancone, Germana, Barber, Bridget E, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Llanos-Cuentas, Alejandro, Pukrittayakamee, Sasithon, Rijal, Komal R, Saravu, Kavitha, Sutanto, Inge, Taylor, Walter R J, Thriemer, Kamala, Watson, James A, Guerin, Philippe J, White, Nicholas J, Price, Ric N, Commons, Robert J, Adhikari, Bipin, Alam, Mohammad Shafiul, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Khan, Wasif Ali, Koh, Gavin CKW, Mekuria, Asrat Hailu, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Pasaribu, Ayodhia Pitaloka, Price, David J, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna · 2024 · The Lancet Infectious Diseases
Cited by 42

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(23)00431-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 38

  1. Douglas, 2014, Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia, BMC Med, 12, 217, 10.1186/s12916-014-0217-z · DOI
  2. Chu, 2021, The prevention and treatment of Plasmodium vivax malaria, PLoS Med, 18, 10.1371/journal.pmed.1003561 · DOI · Paper page
  3. Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map, PLoS Med, 9, 10.1371/journal.pmed.1001339 · DOI · Paper page
  4. Gómez-Manzo, 2016, Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world, Int J Mol Sci, 17, 10.3390/ijms17122069 · DOI · Paper page
  5. Domingo, 2019, Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities, Int Health, 11, 7, 10.1093/inthealth/ihy060 · DOI · Paper page
  6. Thriemer, 2017, Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group, Malar J, 16, 141, 10.1186/s12936-017-1784-1 · DOI · Paper page
  7. Commons, 2017, The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials, Int J Parasitol Drugs Drug Resist, 7, 181, 10.1016/j.ijpddr.2017.03.003 · DOI
  8. Commons, 2019, The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis, BMC Med, 17, 151, 10.1186/s12916-019-1386-6 · DOI · Paper page
  9. Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
  10. White, 2018, Anaemia and malaria, Malar J, 17, 371, 10.1186/s12936-018-2509-9 · DOI · Paper page
  11. Lee, 2008, The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria, Malar J, 7, 149, 10.1186/1475-2875-7-149 · DOI
  12. Hasugian, 2007, Dihydroartemisinin–piperaquine versus artesunate–amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria, Clin Infect Dis, 44, 1067, 10.1086/512677 · DOI · Paper page
  13. Pukrittayakamee, 2010, A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand, Am J Trop Med Hyg, 82, 542, 10.4269/ajtmh.2010.09-0428 · doi:10.4269/ajtmh.2010.09-0428
  14. Barber, 2013, A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy, Clin Infect Dis, 56, 383, 10.1093/cid/cis902 · DOI · Paper page
  15. Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study, Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
  16. Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia, BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
  17. Ley, 2016, G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study, PLoS One, 11, 10.1371/journal.pone.0154015 · DOI
  18. Saravu, 2016, Therapeutic assessment of chloroquine–primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in southwestern India, PLoS One, 11, 10.1371/journal.pone.0157666 · DOI · Paper page
  19. Abreha, 2017, Comparison of artemether–lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial, PLoS Med, 14, 10.1371/journal.pmed.1002299 · DOI · Paper page
  20. Awab, 2017, Chloroquine–primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial, Am J Trop Med Hyg, 97, 1782, 10.4269/ajtmh.17-0290 · DOI · Paper page
  21. Chu, 2018, Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine–primaquine in Plasmodium vivax malaria, Clin Infect Dis, 67, 1543, 10.1093/cid/ciy319 · DOI · Paper page
  22. Grigg, 2018, Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors of severity, Clin Infect Dis, 67, 350, 10.1093/cid/ciy065 · DOI
  23. Chu, 2019, Chloroquine versus dihydroartemisinin–piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria, Clin Infect Dis, 68, 1311, 10.1093/cid/ciy735 · DOI
  24. Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
  25. Ladeia-Andrade, 2019, Monitoring the efficacy of chloroquine–primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil, Antimicrob Agents Chemother, 63, e01965, 10.1128/AAC.01965-18 · DOI · Paper page
  26. Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
  27. Rijal, 2019, Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal, J Infect Dis, 220, 448, 10.1093/infdis/jiz126 · DOI · Paper page
  28. Edgcomb, 1950, Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report, J Natl Malar Soc, 9, 285
  29. Commons, 2023, Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis, Lancet Infect Dis
  30. Thriemer, 2021, Towards the elimination of Plasmodium vivax malaria: implementing the radical cure, PLoS Med, 18, 10.1371/journal.pmed.1003494 · DOI
  31. Douglas, 2013, Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study, PLoS Med, 10, 10.1371/journal.pmed.1001575 · DOI · Paper page
  32. Bancone, 2017, Prevalences of inherited red blood cell disorders in pregnant women of different ethnicities living along the Thailand–Myanmar border, Wellcome Open Res, 2, 72, 10.12688/wellcomeopenres.12338.1 · DOI
  33. Chu, 2017, Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens, PLoS Med, 14, 10.1371/journal.pmed.1002224 · DOI · Paper page
  34. Pal, 2019, Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient, Am J Trop Med Hyg, 100, 213, 10.4269/ajtmh.18-0612 · DOI · Paper page
  35. Sadhewa, 2023, A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria, Pathogens, 12, 650, 10.3390/pathogens12050650 · DOI
  36. Brito-Sousa, 2022, Quantitative G6PD deficiency screening in routine malaria diagnostic units in the Brazilian Amazon (SAFEPRIM): an operational mixed-methods study, Pathogens, 11, 10.3390/pathogens11111328 · DOI
  37. Ley, 2022, Variation in glucose-6-phosphate dehydrogenase activity following acute malaria, PLoS Negl Trop Dis, 16, 10.1371/journal.pntd.0010406 · DOI
  38. Pukrittayakamee, 2023, Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency, eLife, 12

Cited by

See all 42

Metadata

Authors
Rajasekhar, M., Simpson, J. A., Ley, B., Edler, P., Chu, C. S., Abreha, T., Awab, G. R., Baird, J. K., Bancone, G., Barber, B. E., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Llanos-Cuentas, A., Pukrittayakamee, S., Rijal, K. R., Saravu, K., Sutanto, I., Taylor, W. R. J., Thriemer, K., Watson, J. A., Guerin, P. J., White, N. J., Price, R. N., Commons, R. J., Adhikari, B., Alam, M. S., Anstey, N. M., Assefa, A., Boyd, S. C., Chau, N. H., Day, N. P., Degaga, T. S., Dondorp, A. M., Ferreira, M. U., Ghimire, P., Green, J. A., Khan, W. A., Koh, G. C., Mekuria, A. H., Naadim, M. N., Nelwan, E. J., Nosten, F., Pasaribu, A. P., Price, D. J., Stepniewska, K., von Seidlein, L., William, T., Woodrow, C. J., & Woyessa, A.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2024-02
Volume
24
Issue
2
Pages
184-195
ISSN
1473-3099
Cited by
42
References
2
Language
en
Licence
Funders
  • National Health and Medical Research Council (2017436, 2008501, 2016792, 1196068, 1194702)
  • Bill & Melinda Gates Foundation
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (093956/Z/10/C, 223253/Z/21/Z)
  • Capability Systems Centre
  • Centers for Disease Control and Prevention
  • Wellcome Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(23)00431-0
The paper
Rajasekhar, M., Simpson, J. A., Ley, B., Edler, P., Chu, C. S., Abreha, T., Awab, G. R., Baird, J. K., Bancone, G., Barber, B. E., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Llanos-Cuentas, A., Pukrittayakamee, S., Rijal, K. R., Saravu, K., . . . Woyessa, A. (2024). Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(23)00431-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.